CORRECT: Arcontech profit and sales fall; Kromek profit tops forecast
(Corrects the financial 2026 gross margin figure for Fusion Antibodies PLC to 58.3%.) Read More
| Price | 1.70p on 05-10-2026 at 16:30:01 |
|---|---|
| Change | -0.115p -6.76% |
| Buy | 1.80p |
| Sell | 1.60p |
| Last Trade: | Unknown 300.00 at 1.585p |
| Day's Volume: | 2,356,113 |
| Last Close: | 1.585p |
| Open: | 1.70p |
| ISIN: | GB00B03CJS30 |
| Day's Range | 1.585p - 1.585p |
| 52wk Range: | 1.10p - 2.30p |
| Market Capitalisation: | £20.87m |
| VWAP: | 1.715695p |
| Shares in Issue: | 1.32b |
Sector: Fossil Fuels
Listed In: FTSE AIM All-Share,
Europa Oil & Gas (EOG) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Unknown* | 300 | 1.585p | OTC Trade |
16:35:40 - 05-Oct-26 |
| Sell* | 300 | 1.585p | Uncrossing Trade |
16:35:16 - 05-Oct-26 |
| Sell* | 263 | 1.60p | Ordinary |
15:59:51 - 05-Oct-26 |
| Sell* | 12,000 | 1.60p | Ordinary |
15:02:32 - 05-Oct-26 |
| Buy* | 33,898 | 1.77p | Ordinary |
14:14:49 - 05-Oct-26 |
| Buy* | 7,799 | 1.77p | Ordinary |
13:45:06 - 05-Oct-26 |
| Buy* | 16,000 | 1.77p | Ordinary |
12:49:22 - 05-Oct-26 |
| Sell* | 500,000 | 1.68p | Ordinary |
12:15:18 - 05-Oct-26 |
| Sell* | 60 | 1.60p | SI Trade |
11:24:52 - 05-Oct-26 |
| Buy* | 296 | 1.80p | SI Trade |
11:24:52 - 05-Oct-26 |
Europa Oil & Gas (EOG) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 30th Sep 2026 7:00 am | RNS | Update on EG-08 Farm-out Agreement |
| 14th Sep 2026 7:00 am | RNS | Interim Results |
| 1st Sep 2026 7:00 am | RNS | Update on EG-08 Farm-out Agreement |
| 31st Jul 2026 12:05 pm | RNS | Holding(s) in Company |
| 31st Jul 2026 7:00 am | RNS | Update on EG-08 Farm-out Agreement |
| 29th Jul 2026 7:00 am | RNS | Exercise of Options and Total Voting Rights |
| 9th Jul 2026 9:29 am | RNS | Block Listing Application to AIM |
| 29th Jun 2026 1:10 pm | RNS | Result of AGM |
| 26th Jun 2026 7:00 am | RNS | Appointment of Nominated Adviser and Broker |
| 22nd Jun 2026 9:21 am | RNS | Director/PDMR Shareholding |